Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence DEAGSEADHEGTHSTKRGHAKSRP
Primary information
sequence IDSeq_1207
Peptide sequenceDEAGSEADHEGTHSTKRGHAKSRP
CancerPDF_ID CancerPDF_ID3755, CancerPDF_ID8537, CancerPDF_ID10599,
PMID27026199,23667664,21805675
Protein Name"Fibrinogen alpha chain, Fibrinogen alpha chain",Fibrinogen alpha,Fibrinogen alpha chain
UniprotKB Entry NameFIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN
FluidUrine,Serum,Urine
M/ZNA,2559.18,2560.1784
ChargeNA,1,NA
Mass (in Da)NA,2561.65,NA
fdr2559.18,NA,NA
Profiling Technique"CE-MS, Micro-TOF-MS",MALDI-TOF,MALDI-TOF
Peptide Identification techniqueMS-MS,FT-ICR MS/MS + nano-HPLC,MALDI-TOF-MS
Quantification TechniqueNA,NA,NA
Labelled/Label FreeLabel Free,Label Free,Label Free
FDRNA,NA,1
CancerPDF_ID CancerPDF_ID3755, CancerPDF_ID8537, CancerPDF_ID10599,
p-Valueless than 0.01,NA,NA
SoftwareProteome Discoverer 1.2,MASCOT,NA
Length24,24,24
Cancer TypeBladder cancer,"Breast cancer, Lung cancer, Rectal cancer",Muscle-invasive bladder cancer
DatabaseUniprot Human non-redundant Database,NA,SwissProt Database
ModificationNA,NA,NA
Number of Patients 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls),"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",751 bladder cancer and 127 control
RegulationDifferentially expressed between recurrence of UBC vs recurrence control,NA,Differentially expressed between cancer vs normal samples
ValidationIndependent Validation,NA,Mann-Whitney tests and areas under receiver-operator characteristic
SensitivityFor testing dataset 88%,NA,NA
SpecificityFor testing dataset 51%,NA,NA
AccuracyNA,NA,NA
Peptide AtlasNA
IEDB